Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reactivity to type I interferon is key to predict cancer immunotherapy response

The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: IFN-I responsiveness predicts survival after anti-PD1 therapy.


  1. Gellrich, F. F. et al. Anti-PD-1 and novel combinations in the treatment of melanoma–an update. J. Clin. Med. 9, 223 (2020). This paper reviews different ICI combinations and their response rates across many different clinical trials in patients with metastatic melanoma.

    Article  CAS  Google Scholar 

  2. Boukhaled, G. M. et al. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167–198 (2021). A comprehensive review of the diverse roles of IFN-I in cancer cells and tumor immunology.

    Article  CAS  Google Scholar 

  3. Benci, J. L. et al. Opposing functions of interferon coordinate adaptive and innate immune response to cancer immune checkpoint blockade. Cell 178, 933–948 (2019). A paper reporting that IFNs exert distinct and opposing functions on tumor and immune cells, limiting tumor cell death.

    Article  CAS  Google Scholar 

  4. Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017). An Article that shows that higher IFN-II response in the tumor positively correlates with patient outcome.

    Article  Google Scholar 

  5. Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigen stimulation. Nat. Immunol. 22, 1008–1019 (2021). This study demonstrates that exhausted T cells with epigenetic scars fail to develop into functional memory T cells.

    Article  CAS  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Boukhaled, G. M. et al. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat. Immunol. (2022).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reactivity to type I interferon is key to predict cancer immunotherapy response. Nat Immunol 23, 1146–1147 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer